User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

15662

Interactions with Platform & by Email *

INTERACTIONS

1566

Unique # Participated *

PARTICIPANTS

313

Responses Validated *

VALIDATIONS

47

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Biologics: Taking over the Conventional Drugs Market.....II-1
Table 1: Increasing Share of Biologics in the Global Pharmaceutical Market: 2013-2020 (includes corresponding Graph/Chart).....II-1
1$350
   Table 2: Percentage Share of Pipeline Drugs for Biologics vs. Small Molecules (2014) (includes corresponding Graph/Chart).....II-2
Current and Future Analysis.....II-2
Competition.....II-2
1$350
   Table 3: Leading Players in the Global Biopharmaceuticals Market (2014E): Percentage Market Share Breakdown of Value Sales for AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Roche, Sanofi, and Others (includes corresponding Graph/Chart).....II-31$350
   Table 4: Leading Brands in the Global Biopharmaceuticals Market (2014E): Percentage Market Share Breakdown of Revenues for Avastin, Enbrel, Herceptin, Humira, Lantus, Lucentis, Neulasta, Novolog/NovoRapid, Remicade, Rituxan, and Others (includes corresponding Graph/Chart).....II-4
Intensifying Consolidation Activity.....II-4
1$350
   Recent M&A Activity in the Biologics Industry: 2014 & 2015.....II-5
2015: A year of Patent Expiries for Biologics.....II-5
Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe.....II-5
1$100
   Market Drivers.....II-61$100
   Growing Aging Population.....II-7 1$100
   Table 5: Global Population Statistics for the 65+ Age Group: 2013 (includes corresponding Graph/Chart).....II-81$350
   Table 6: Life Expectancy by Select Countries: 2013 (includes corresponding Graph/Chart).....II-9
Market Restraints.....II-9
1$350
   Affordability.....II-10
Complex Supply Chain.....II-10
Quality and Regulatory Issues.....II-10
2014-15: A Launch-Driven Period for Biopharmaceuticals.....II-10
1$100
   Recently Approved Biopharmaceuticals: 2013, 2014 & 2015.....II-112$200
   R&D Funding Crucial.....II-13
Table 7: Global Biopharmaceutical R&D Expenditure: 2010- 2015E (includes corresponding Graph/Chart).....II-13
1$350
   Monoclonal Antibodies – The Most Viable Biopharmaceutical Segment.....II-14 1$100
   Table 8: Global Monoclonal Antibody Market by Leading Player (2014E) - Percentage Share of Value Sales for AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Roche, and Others (includes corresponding Graph/Chart).....II-15

Table 9: Global Monoclonal Antibody Market by Leading Brand (2014E) - Percentage Share of Value Sales for Avastin, Enbrel, Herceptin, Humira, Remicade, Rituxan, and Others (includes corresponding Graph/Chart).....II-15
1$350
   Approved Monoclonal Antibodies for Therapeutic Use: 1986-2014.....II-161$100
   Opportunity Indicators.....II-17
Cancer Incidence.....II-17
Table 10: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).....II-17
1$350
   Table 11: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).....II-18
Rheumatoid Arthritis Prevalence.....II-18
1$350
   Table 12: Projections of Rheumatoid Arthritis Prevalence in the US in Millions (2010-2030) (includes corresponding Graph/Chart).....II-19

Table 13: Prevalence of Treated Rheumatoid Arthritis in South Africa (Rate per 1000 Beneficiaries): 2008-2013 (includes corresponding Graph/Chart).....II-19
Insulin – Segment with High Potential.....II-19
1$350
   Competitive Landscape.....II-20
List of Different Insulin Brands of the Three Major Players by Type.....II-20
Table 14: Global Insulin Market by Brand (2014E): Percentage Share of Value sales for Apidra, Humalog, Humulin, Insuman, Lantus, Levimir, NovoMix, NovoRapid, and Others (includes corresponding Graph/Chart).....II-20
1$350
   Comparative Analysis of New Insulin Basal Analogs.....II-21 1$100
   Table 15: Global Basal Insulin Market by Brand (2016-2020E): Percentage Market Share Breakdown of Revenues for Basalgar, Lantus, Levemir, Peg Lispro, Toujeo, and Tresiba (includes corresponding Graph/Chart).....II-221$350
   Opportunity Indicator.....II-23
Diabetes Prevalence & Incidence.....II-23
Table 16: Global Diabetes Mellitus Prevalence by Geographic Region (2014E & 2035P): Prevalence (in Millions) and Percentage Share (includes corresponding Graph/Chart).....II-23
1$350
   Table 17: Percentage Increase in DM Incidence among Ages 20-79 Worldwide by Geographic Region: 2013-2035 (includes corresponding Graph/Chart).....II-241$350
   Table 18: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2014E & 2035P (includes corresponding Graph/Chart).....II-25
Recombinant Therapeutic Proteins.....II-25
2$350
   Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy.....II-27
Blood Growth Factors: Improving Circulation & Mobility in Peripheral Artery Disease
  Patients.....II-27
Wound Management Market and Cellular Growth Factors.....II-27
1$100
   Multiple Sclerosis Drugs Market: Competition Set to Intensify.....II-281$100
   Interferon-based Drugs for HCV Treatment: An Insight.....II-291$100
   Vaccine Market Dynamics.....II-30 1$100
   Table 19: Global Vaccines Market by Leading Player (2014) - Percentage Share of Value Sales for GSK, Merck, Novartis Flu Vaccines, Pfizer, Sanofi, SP-MSD & Others (includes corresponding Graph/Chart).....II-31
Growth Drivers in a Capsule.....II-31
Pediatric Vaccines: A Lucrative Segment.....II-31
1$350
   Table 20: Number of Reported Cases for Vaccine-Preventable Diseases Globally: 2009-2013 (includes corresponding Graph/Chart).....II-321$350
   Table 21: Global Pediatric Vaccines Market by Leading Players (2013): Percentage Market Share Breakdown of Dollar Sales for GlaxoSmithKline, Novartis, Sanofi-Pasteur, Merck, and Others (includes corresponding Graph/Chart).....II-33
Hepatitis B Combination Vaccines to Propel Market Growth.....II-33
Conjugated and Protein-based Vaccines to Take over Polysaccharide Vaccines for
  Infectious Diseases.....II-33
1$350
   DNA Vaccines: Engineering Growth.....II-342$200
   Table 22: Biopharmaceutical Products’ Pipeline by Therapeutic Category (2015) (includes corresponding Graph/Chart).....II-361$350
   Table 23: No. of Pipeline Biopharmaceuticals for Cancer by Site (2015) (includes corresponding Graph/Chart).....II-37

Table 24: No. of Pipeline Biopharmaceuticals for HIV/AIDS Treatment by Type of Therapy (2015) (includes corresponding Graph/Chart).....II-37
Insulin Products in Development.....II-37
1$350
   List of Newly Approved and Pipeline Insulin Products: 2015.....II-381$100
   Disposable Systems Favored for Manufacturing.....II-39
Innovations in Single-use Systems.....II-39
1$100
   Increasing Appeal of Biosimilars.....II-40
Table 25: Global Biosimilars Market Size Estimates and Forecasts: 2012-2018F (includes corresponding Graph/Chart).....II-40
1$350
   Supply Chain Management Crucial for Clinical Trials.....II-41
Plant-based Production Scores over Mammalian Cell Culture Systems.....II-41
Safety & Efficacy Issues Concerning Erythropoietin Stimulating Agents (ESAs).....II-41
hMSC-based Therapies to Drive Need for Growth Factors.....II-41
1$100
   Stem Cell Therapies Gain Popularity.....II-42
Development of Cost Effective Methods – Need of the Hour.....II-42
1$100
   M&A Activity to Maintain Momentum.....II-43
Key Factors Determining Long-Term Success.....II-43
1$100
   Innovations.....II-44
Peptide against Skin Cancer.....II-44
1$100
   Monoclonal Antibodies to Treat Ebola.....II-451$100
   Regulatory Environment for Biopharmaceuticals’ Manufacture & Storage.....II-46
Glossary of Terms.....II-46
1$100
   Evolution of Biopharmaceuticals.....II-47
Biopharmaceutical Manufacturing.....II-47
1$100
   Bioprocess Membrane Technology.....II-48
Disposable Manufacturing with Single-Use Systems.....II-48
Major Concerns Related to the Production of Biopharmaceuticals.....II-48
1$100
   Future of Biopharmaceutical Manufacturing.....II-49
Marketing Approval for Biopharmaceuticals.....II-49
Techniques to Characterize Biopharmaceuticals.....II-49
1$100
   Biopharmaceuticals – Types and Therapeutic Applications.....II-50
Insulin.....II-50
Monoclonal Antibodies.....II-50
1$100
   Recombinant Proteins.....II-51
Cytokines.....II-51
1$100
   Interferon.....II-52
Colony Stimulating Factors (CSF).....II-52
Erythropoietin (EPO).....II-52
Clotting Factors.....II-52
1$100
   Vaccines.....II-53
Types of Vaccines.....II-53
Live, Attenuated Vaccines.....II-53
1$100
   Combination Vaccines.....II-54
Killed or Inactivated Vaccines.....II-54
1$100
   DNA & Recombinant DNA Vaccines.....II-551$100
   Toxoids.....II-56
Subunit Vaccines.....II-56
1$100
   Mexican Health Authority, COFEPRIS, Approves Biocon’s Insulin Glargine.....II-57
Shantha Biotechnics Delivers 400,000 doses of Shan5 Vaccine.....II-57
Amyris to Launch µPharm platform for Biotherapeutics Production.....II-57
FDA Approves IMBRUVICA for New Indication.....II-57
FDA Approves Cosentyx™ by Novartis.....II-57
Hospira Submits BLA for the Biosimilar Retacrit.....II-57
Celestial Biolabs to Launch Antibiotic for Diabetes.....II-57
1$100
   MHRA Validates RedHill Biopharma’s Bekinda MAA.....II-58
Zydus Cadila Launches Adalimumab Biosimilar.....II-58
EPIRUS Launches Infimab.....II-58
KYTHERA Biopharmaceuticals Submits NDS for ATX-101.....II-58
FDA Accepts New Drug Application of KYTHERA’s ATX-101.....II-58
FDA Approves sNDA for Lymphoseek by Navidea.....II-58
Hospira’s Biosimilar Inflectra Launched in Central and Eastern Europe.....II-58
1$100
   Sun Pharmaceuticals Integrates Ranbaxy.....II-59
Baxter Acquires SuppreMol GmbH.....II-59
Baxalta to Separate from Baxter and Change Headquarters.....II-59
Matinas BioPharma Holdings Acquires Aquarius BioTechnologies.....II-59
3SBio Acquires Sirton Pharmaceuticals SpA.....II-59
Pfizer to Acquire Hospira.....II-59
1$100
   Roche to Acquire Trophos.....II-60
Novartis Completes Transaction with GSK.....II-60
Johnson & Johnson Forms Ebola Vaccine Development Consortia.....II-60
Boehringer Ingelheim and Sanofi Enter Strategic Manufacturing Agreement.....II-60
OnCore Biopharma and Tekmira Enter Merger Agreement.....II-60
Regado Biosciences and Tobira Enter Merger Agreement.....II-60
1$100
   WuXi PharmaTech Acquires NextCODE Health.....II-61
Adaptive Biotechnologies to Acquire Sequenta.....II-61
Cardio3 BioSciences Acquires OnCyte.....II-61
FUJIFILM Diosynth Biotechnologies Acquires Kalon Biotherapeutics.....II-61
Prima BioMed Completes Acquisition of Immutep.....II-61
BioMarin Pharmaceutical Acquires ProSensa Holding.....II-61
Ricerca Biosciences Acquired by Investment Group Main Market Partners.....II-61
1$100
   GE Healthcare Life Sciences to Open Biopharmaceutical Laboratory in Turkey.....II-62
Johnson & Johnson Acquires Alios BioPharma.....II-62
PDL Biopharma Acquires Part of Cerdelga Royalties.....II-62
DPx Holdings B.V. Acquires Gallus BioPharmaceuticals.....II-62
Sunshine Biopharma Forms Canadian Subsidiary.....II-62
Albany Molecular Research Inc. (AMRI) Acquires OSO Biopharmaceuticals.....II-62
Pall Corporation Acquires New Biopharmaceutical Production Technologies.....II-62
1$100
   Actavis Plc. Acquires Forest Laboratories.....II-63
Roche to Acquire InterMune.....II-63
CSL Acquires Influenza Vaccines Business of Novartis.....II-63
1$100
   AbbVie, Inc. (US).....II-64
Anavex Life Sciences Corp. (US).....II-64
Baxter International, Inc. (US).....II-64
1$100
   Bayer HealthCare Pharmaceuticals, Inc. (US).....II-65
Biocon (India).....II-65
Eli Lilly (US).....II-65
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-66
Genentech (US).....II-66
GlaxoSmithKline (UK).....II-66
1$100
   Janssen Biotech, Inc. (US).....II-67
Kemwell Biopharma (India).....II-67
Novartis (Switzerland).....II-67
1$100
   Sandoz.....II-68
Pfizer, Inc. (US).....II-68
1$100
   Sun Pharmaceutical Industries Ltd. (India).....II-69
Sanofi S.A. (France).....II-69
2$200
   Table 26: World Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-711$350
   Table 27: World Historic Review for Biopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-721$350
   Table 28: World 14-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-731$350
   Biopharmaceuticals Market by Product Segment.....II-74
Table 29: World Recent Past, Current & Future Analysis for Recombinant Protein by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-74
1$350
   Table 30: World Historic Review for Recombinant Protein by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-751$350
   Table 31: World 14-Year Perspective for Recombinant Protein by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-761$350
   Table 32: World Recent Past, Current & Future Analysis for Monoclonal Antibodies (mAbs) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-771$350
   Table 33: World Historic Review for Monoclonal Antibodies (mAbs) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-781$350
   Table 34: World 14-Year Perspective for Monoclonal Antibodies (mAbs) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-791$350
   Table 35: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-801$350
   Table 36: World Historic Review for Insulin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-811$350
   Table 37: World 14-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-821$350
   Table 38: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....II-831$350
   Table 39: World Historic Review for Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....II-841$350
   Table 40: World 14-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....II-851$350
   A. Market Analysis.....III-1
United States: The Largest Biopharmaceutical Market Globally.....III-1
Table 41: No. of Biologics Approved by the Center for Biologics Evaluation and Research (CBER): 2003-2013 (includes corresponding Graph/Chart).....III-1
1$200
   A R&D Driven Industry.....III-2
Impending Patent Expiries.....III-2
1$75
   Table 42: Leading US Biopharmaceuticals by Revenue (in US$ Billion) and Year of Patent Expiry (includes corresponding Graph/Chart).....III-3
Biosimilars and the Implications of the BPCI Act.....III-3
1$200
   Segment Analysis.....III-4
Monoclonal Antibodies.....III-4
Opportunity Indicators.....III-4
Rheumatoid Arthritis Incidence.....III-4
Table 43: Rheumatoid Arthritis Prevalence in the US in Millions (2010-2030) (includes corresponding Graph/Chart).....III-4
1$200
   Table 44: The US Cancer Incidence by Gender (2014): No. of Reported New Cases for Men and Women (includes corresponding Graph/Chart).....III-5

Table 45: The US Cancer Incidence by Affected Site (2014): Number of New Cancer Cases (includes corresponding Graph/Chart).....III-5
Recombinant Proteins.....III-5
1$200
   Erythropoietin (EPO) Market: Amgen Continues to Dominate.....III-6
Interferon Market: An Insight.....III-6
1$75
   Colony Stimulating Factors (CSF) Market: An Overview.....III-7
Table 46: The US Short Acting Granulocyte Colony Stimulating Factors (G-CSFs) Market (2014 & 2020): Percentage Share Breakdown of Volume Sales for HSP Nivestim, Neupogen, Sandoz EP2006, and TEVA Granix (includes corresponding Graph/Chart).....III-7
1$200
   Table 47: The US Long Acting Granulocyte Colony Stimulating Factors (G-CSFs) Market (2014 & 2020): Percentage Share Breakdown of Volume Sales for HSP peg-Filgrastim, Neulasta, Sandoz LA-EP2006, and TEVA Balugrastim (includes corresponding Graph/Chart).....III-8
Vaccines Industry in the US.....III-8
1$200
   Federal Research & Grants.....III-9
National Cancer Institute.....III-9
National Institutes of Health (NIH).....III-9
Pediatric Vaccines Market Witnesses Rapid Growth.....III-9
1$75
   Opportunity Indicator.....III-10
Table 48: Number of Reported Cases for Vaccine-Preventable Diseases in American Regions (includes corresponding Graph/Chart).....III-10
1$200
   Table 49: Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-11
Select Market Trends.....III-11
Manufacturers Shift Focus to Small Bioreactors.....III-11
1$200
   Biosimilar Developers Face Higher Litigation Risks.....III-12
Varying Biosimilar Prescription Rules across the Country.....III-12
1$75
   Regulatory Scenario.....III-13
Combination Products Pose Challenges to Manufacturers.....III-13
FDA Efforts to Mitigate Concerns.....III-13
FDA Announces New Labeling Guidelines for Biologics and Prescription Drugs.....III-13
1$75
   Product Launches.....III-141$75
   Strategic Corporate Developments.....III-152$150
   Select Key Players.....III-173$225
   B. Market Analytics.....III-20
Table 50: The US Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-20
1$200
   Table 51: The US Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-211$200
   Table 52: The US 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-221$200
   A. Market Analysis.....III-23
Lucrative Partnership Opportunities for Global Players.....III-23
Mabs Lead, Insulin Exhibits Faster Growth.....III-23
1$75
   Table 53: Prevalence of Diabetes Mellitus in Canada (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group (includes corresponding Graph/Chart).....III-24
Strategic Corporate Developments.....III-24
1$200
   B. Market Analytics.....III-25
Table 54: Canadian Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-25
1$200
   Table 55: Canadian Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-261$200
   Table 56: Canadian 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-271$200
   A. Market Analysis.....III-28
Erythropoietin Market.....III-28
Leading EPO Drugs in Japan.....III-28
HCV Infection: Combination Therapy Dominates.....III-28
1$75
   Diabetes Prevalence: Opportunity Indicator for the Insulin Market.....III-29
Table 57: Prevalence of Diabetes Mellitus in Japan (2013): Number of People with DM (in thousands) by Age Group (includes corresponding Graph/Chart).....III-29
1$200
   B. Market Analytics.....III-30
Table 58: Japanese Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-30
1$200
   Table 59: Japanese Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-311$200
   Table 60: Japanese 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-321$200
   A. Market Analysis.....III-33
Funding Challenges Faced by Biopharmaceutical Startups.....III-33
Healthcare Agencies Looking to Embrace Biosimilars to Cut Healthcare Costs.....III-33
1$75
   Table 61: European Biosimilar Market by Leading Player (2014): Percentage Market Share of Value Sales for Hospira, Sandoz, Teva, and Others (includes corresponding Graph/Chart).....III-34

Table 62: Biosimilar Penetration in Select EU Countries (2013).....III-34
1$200
   Biosimilars Currently Licensed in Europe.....III-35
Regulatory Scenario.....III-35
Erythropoietin Market.....III-35
Leading EPO Drugs in Europe.....III-35
1$75
   B. Market Analytics.....III-36
Table 63: European Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-36
1$200
   Table 64: European Historic Review for Biopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-371$200
   Table 65: European 14-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-381$200
   Table 66: European Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-391$200
   Table 67: European Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-401$200
   Table 68: European 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-411$200
   A. Market Analysis.....III-42
Sanofi S.A. – A Key Player.....III-42
1$75
   B. Market Analytics.....III-43
Table 69: French Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-43
1$200
   Table 70: French Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-441$200
   Table 71: French 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-451$200
   A. Market Analysis.....III-46
Strategic Corporate Development.....III-46
1$75
   B. Market Analytics.....III-47
Table 72: German Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-47
1$200
   Table 73: German Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-481$200
   Table 74: German 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-491$200
   Market Analysis.....III-50
Table 75: Italian Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-50
1$200
   Table 76: Italian Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-511$200
   Table 77: Italian 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-521$200
   A. Market Analysis.....III-53
Strategic Corporate Development.....III-53
Glaxosmithkline – A Key Player.....III-53
1$75
   B. Market Analytics.....III-54
Table 78: The UK Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-54
1$200
   Table 79: The UK Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-551$200
   Table 80: The UK 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-561$200
   Market Analysis.....III-57
Table 81: Spanish Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-57
1$200
   Table 82: Spanish Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-581$200
   Table 83: Spanish 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-591$200
   A. Market Analysis.....III-60
Russia Sets Eyes on Emerging as a Notable Pharmaceutical Market.....III-60
Encouraging Local Manufacturing.....III-60
1$75
   Challenges - Need for Extensive R&D.....III-611$75
   B. Market Analytics.....III-62
Table 84: Russian Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-62
1$200
   Table 85: Russian Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-631$200
   Table 86: Russian 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-641$200
   A. Market Analysis.....III-65
Product Launches.....III-65
Strategic Corporate Developments.....III-65
1$75
   Select Key Players.....III-662$150
   B. Market Analytics.....III-68
Table 87: Rest of European Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-68
1$200
   Table 88: Rest of European Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-691$200
   Table 89: Rest of European 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-701$200
   A. Market Analysis.....III-71
Regional Biopharma Players Gain Strength by Innovation and Partnerships.....III-71
Asia Set to Emerge as Preferred Outsourcing Destination for Biopharma
  Manufacturing.....III-71
1$75
   Availability of Scientific Talent – Major Advantage for India.....III-72
Primary Challenges for Asian CMOs.....III-72
1$75
   China – An Untapped Market for Antitumor mAbs.....III-73
List of Anti-Cancer Monoclonal antibodies Approved by China Food & Drug
  Administration.....III-73
1$75
   Table 90: Chinese Biopharmaceuticals Market by Segment (2014): Percentage Share Breakdown of Value Sales for EPO, G-CSF, Insulin, Interferon, Interleukin, mAb, Nerve Growth Factors, and Others (includes corresponding Graph/Chart).....III-74
Chinese Erythropoietin Market.....III-74
1$200
   Table 91: Leading Players in the Chinese EPO Market (2014): Percentage Share Breakdown of Value Sales for 3SBio, Beijing Sihuan, Harbin Pharma, Nanjin Huaxin Pharma, and Others (includes corresponding Graph/Chart).....III-75
Injectable Interferons: The Only Treatment for HCV Patients.....III-75
1$200
   Table 92: Interferon Market in China (2014): Percentage Share Breakdown of Value Sales by Type of Interferon (includes corresponding Graph/Chart).....III-76

Table 93: Leading Players in the Chinese Interferons Market (2014): Percentage Share Breakdown of Value Sales for Hualida Bio, Huaxin Bio, Merck, Roche, Sinovac, Tri-Prime Gene, and Others (includes corresponding Graph/Chart).....III-76
1$200
   Hepatitis B Market: Smaller Role of Interferons.....III-77
G-CSF Market: Competitive Landscape.....III-77
Table 94: G-CSF Market in China by Agent (2014): Percentage Share Breakdown of Revenues for Filgrastim, Lenograstim, Molgramostim, Nartograstim, and Others (includes corresponding Graph/Chart).....III-77
1$200
   Table 95: Leading Manufacturers in the Chinese G-CSF Market (2014): Percentage Share Breakdown of Revenues for Hangzhou Jiuyuan, Jiangsu Wuzhong Pharma, Qilu Pharma, Roche, Xiamen Amoytop Bio, Xiehe Fajio Qilin, and Others (includes corresponding Graph/Chart).....III-78
Interleukins Market.....III-78
Table 96: Interleukins Market in China (2014): Percentage Share Breakdown of Value Sales by Type - Interleukin-11 and Interleukin-2 (includes corresponding Graph/Chart).....III-78
1$200
   Table 97: Leading Players in the Chinese Interleukins Market (2014): Percentage Share Breakdown of Value Sales for E China Pharm, Four Rings, QG Pharm, Qilu Pharm, SL Pharm, and Others (includes corresponding Graph/Chart).....III-79
Cell Therapies Gaining Ground in Korea.....III-79
Product Launches.....III-79
1$200
   Strategic Corporate Developments.....III-801$75
   Select Key Players.....III-811$75
   B. Market Analytics.....III-82
Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-82
1$200
   Table 99: Asia-Pacific Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-831$200
   Table 100: Asia-Pacific 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-841$200
   A. Market Analysis.....III-85
Lack of Access Impedes Market in Developing Economies.....III-85
Interferons Widely Used in HCV Therapeutics in Brazil.....III-85
1$75
   Product Launches.....III-861$75
   B. Market Analytics.....III-87
Table 101: Rest of World Recent Past, Current & Future Analysis for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart).....III-87
1$200
   Table 102: Rest of World Historic Review for Biopharmaceuticals by Segment - Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).....III-881$200
   Table 103: Rest of World 14-Year Perspective for Biopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).....III-891$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com